Ionis Pharmaceuticals, Inc.(IONS)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
IONS | 9.66 B | -16.70x | -40.70% | -64.66% | $-3.48 | -1.05% | 4.98 | - | $86.74 | $49.13 |
MRNA | 59.43 B | -18.66x | 2.10% | -1.41% | $-7.98 | -39.00% | 0.19 | - | $176.66 | $22.28 |
NBIX | 16.10 B | 23.15x | 39.50% | 20.91% | $6.84 | 22.09% | 0.13 | - | $186.12 | $122.14 |
BBIO | 14.74 B | -21.18x | 1.20% | -97.03% | $-3.56 | - | - | - | $93.42 | $48.78 |
EXEL | 14.65 B | 18.59x | 10.60% | 35.33% | $3.18 | 44.39% | 9.00 | - | $57.57 | $33.76 |
Peer Valuation & Performance Analysis
Peer group analysis for Ionis Pharmaceuticals, Inc. (IONS) compared to its primary competitors (including MRNA, NBIX, BBIO) reveals distinct metrics. IONS trades at a valuation discount relative to its competitors, with a P/E ratio of -16.7x versus the peer average of 0.5x (representing a 3604% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, IONS's revenue growth of -40.7% lags behind the peer average of 13.4%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of -64.7% is below the peer average of -10.6%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• IONS ranks #0 in P/E ratio, #5 in revenue growth, and #4 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $60.42 | $60.42 | $57.47 | $58.13 | 4,343,700 | -3.79% |
| 2026-09-02 | $60.25 | $61.77 | $59.78 | $61.33 | 1,845,200 | +1.79% |
| 2026-09-01 | $60.37 | $60.99 | $59.78 | $59.88 | 1,872,600 | -0.81% |
| 2026-08-31 | $61.07 | $61.07 | $59.70 | $60.36 | 2,017,100 | -1.16% |
| 2026-08-28 | $60.62 | $61.69 | $60.35 | $61.05 | 1,850,900 | +0.71% |
| 2026-08-27 | $63.48 | $63.48 | $62.34 | $62.43 | 1,625,200 | -1.65% |
| 2026-08-26 | $63.50 | $63.55 | $62.44 | $63.36 | 2,152,200 | -0.22% |
| 2026-08-25 | $62.53 | $64.19 | $62.19 | $63.57 | 2,432,000 | +1.66% |
| 2026-08-24 | $60.54 | $62.07 | $59.70 | $62.04 | 2,206,900 | +2.48% |
| 2026-08-21 | $59.64 | $60.92 | $59.06 | $59.74 | 2,723,500 | +0.17% |
| 2026-08-20 | $60.03 | $60.41 | $58.60 | $58.76 | 2,124,800 | -2.12% |
| 2026-08-19 | $60.11 | $61.36 | $59.61 | $60.80 | 3,135,800 | +1.15% |
| 2026-08-18 | $58.41 | $60.19 | $58.02 | $59.62 | 3,192,500 | +2.07% |
| 2026-08-17 | $57.11 | $58.74 | $56.41 | $58.63 | 2,000,200 | +2.66% |
| 2026-08-14 | $55.16 | $57.24 | $55.16 | $57.24 | 1,353,700 | +3.77% |
Explore More Analysis for IONS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.